The lack of association between PD-1/FOXP3 with IDH1 mutational status of the tumor is probably one of the most fascinating findings of our study, which suggests that only a highly select subset of patients will benefit from combinatorial therapeutic options. This evidence concerns the gene FOXP3 and neoplasm.